These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9043854)

  • 1. Prostacyclin and risk of thromboembolism.
    Varela-Aguilar JM; Sánchez-Hueso MC; González-Jimenez MD; García-Contreras RF; González dela Puente MA
    Eur Heart J; 1997 Feb; 18(2):349. PubMed ID: 9043854
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of intravenous prostacyclin in a model of microsurgical thrombosis.
    Bailes JE; Quigley MR; Kwaan HC; Nishiura BR; Cerullo LJ; Lastre C
    Microsurgery; 1988; 9(1):2-9. PubMed ID: 3292871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction.
    Kiernan FJ; Kluger J; Regnier JC; Rutkowski M; Fieldman A
    Br Heart J; 1986 Nov; 56(5):428-32. PubMed ID: 3539163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostacyclin as an Anticoagulant for Continuous Renal Replacement Therapy in Children.
    Deep A; Zoha M; Dutta Kukreja P
    Blood Purif; 2017; 43(4):279-289. PubMed ID: 28118627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease.
    Davis LL; deBoisblanc BP; Glynn CE; Ramirez C; Summer WR
    Chest; 1995 Dec; 108(6):1754-6. PubMed ID: 7497799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin reduces incidence of myocardial damage after coronary endarterectomy.
    Jonjev ZS; Nićin S; Mujović V; Petrović L; Radovanović N
    Ann Thorac Surg; 2004 Oct; 78(4):1299-303. PubMed ID: 15464489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical effect of prostacyclin infusion in a patient with primary pulmonary hypertension-a case report.
    Younger JR; Lui CY
    Angiology; 2004; 55(3):341-4. PubMed ID: 15156270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of delayed onset prostacyclin on markers of endothelial function and damage after subarachnoid hemorrhage.
    Gybel-Brask M; Rasmussen R; Stensballe J; Johansson PI; Ostrowski SR
    Acta Neurochir (Wien); 2017 Jun; 159(6):1073-1078. PubMed ID: 28386837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of prostacyclin infusion in acute myocardial infarction.
    Armstrong PW; Langevin LM; Watts DG
    Am J Cardiol; 1988 Feb; 61(6):455-7. PubMed ID: 3277368
    [No Abstract]   [Full Text] [Related]  

  • 13. Intracoronary prostacyclin in evolving acute myocardial infarction.
    Grose R; Greenberg M; Strain J; Mueller H
    Am J Cardiol; 1985 Jun; 55(13 Pt 1):1625-6. PubMed ID: 3890513
    [No Abstract]   [Full Text] [Related]  

  • 14. Epoprostenol in the treatment of congestive heart failure.
    Phillips BB; Gandhi AJ
    Am J Health Syst Pharm; 1997 Nov; 54(22):2613-5. PubMed ID: 9397226
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
    Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
    J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis.
    Gainza FJ; Quintanilla N; Pijoan JI; Delgado S; Urbizu JM; Lampreabe I
    J Nephrol; 2006; 19(5):648-55. PubMed ID: 17136695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2.
    Cuiper LL; Price PV; Christman BW
    J Appl Physiol (1985); 1996 Jan; 80(1):191-7. PubMed ID: 8847301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous epoprostenol for primary pulmonary hypertension.
    Higenbottam T
    N Engl J Med; 1996 May; 334(22):1477; author reply 1477-8. PubMed ID: 8618595
    [No Abstract]   [Full Text] [Related]  

  • 19. [Selective pulmonary vasodilation during inhalation of aerosol prostacyclin in critically ill patients].
    Schierbeck J; Heslet L
    Ugeskr Laeger; 1997 Oct; 159(42):6226-8. PubMed ID: 9381595
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous epoprostenol for primary pulmonary hypertension.
    Schulze-Neick I; Lange PE; Haas NA
    N Engl J Med; 1996 May; 334(22):1477; author reply 1477-8. PubMed ID: 8618596
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.